BTS
GALT icon

BB&T Securities’s Galectin Therapeutics GALT Stock Holding History

BB&T Securities’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-23,500
Closed -$38K – 1182
2015
Q4 		$38K Buy
+23,500
New +$53.8K ﹤0.01% 1138

Other funds holding GALT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

BB&T Securities's GALT Position: Q1 2016 in Review

BB&T Securities sold out of Galectin Therapeutics (GALT) in Q1 2016, closing a stake of 23,500 shares — an estimated $38K sold.

BB&T Securities first reported a position in GALT in Q4 2015 and held it in 1 quarter. The position peaked at $38K in Q4 2015. 50 funds tracked by Wall St. Rank hold GALT as of Q1 2016.

  • BB&T Securities reported no remaining Galectin Therapeutics position as of Q1 2016 after selling out during the quarter.
  • BB&T Securities sold 23,500 Galectin Therapeutics shares in Q1 2016, an estimated $38K.
  • BB&T Securities first reported a position in Galectin Therapeutics in Q4 2015 and held it in 1 quarter.
  • BB&T Securities's Galectin Therapeutics position peaked at $38K in Q4 2015.
  • 50 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2016.

Based on BB&T Securities's 13F filing for Q1 2016, filed 12 May 2016.